Skip to main content
NIHPA Author Manuscripts logoLink to NIHPA Author Manuscripts
. Author manuscript; available in PMC: 2018 Jan 16.
Published in final edited form as: Angew Chem Int Ed Engl. 2016 Nov 17;56(3):728–732. doi: 10.1002/anie.201608207

Decarboxylative Peptide Macrocyclization via Photoredox Catalysis

Stefan J McCarver 1, Jennifer X Qiao 2, Joseph Carpenter 3, Robert M Borzilleri 4, Michael A Poss 5, Martin D Eastgate 6, Michael Miller 7, David W C MacMillan 8,*
PMCID: PMC5225041  NIHMSID: NIHMS833804  PMID: 27860140

Abstract

A method for the decarboxylative macrocyclization of peptides bearing N-terminal Michael acceptors has been developed. This synthetic protocol enables the efficient synthesis of γ-amino acid-containing cyclic peptides and is tolerant of functionality present in both natural and non-proteinogenic amino acids. Linear precursors ranging from 3 to 15 amino acids cyclize effectively under this photoredox protocol. To demonstrate the preparative utility of this method in the context of bioactive molecules, we have generated COR-005, a somatostatin analog currently in clinical trials.

Keywords: decarboxylation, macrocycles, Michael addition, peptides, photoredox catalysis

Graphical Abstract

graphic file with name nihms833804f2.jpg

A method for the decarboxylative macrocyclization of peptides bearing N-terminal Michael acceptors has been developed. This synthetic protocol enables the efficient synthesis of γ-amino acid-containing cyclic peptides and is tolerant of functionality present in natural amino acids. Linear precursors ranging from 3 to 15 amino acids cyclize effectively under this photoredox protocol.


Cyclic peptides have recently received significant attention from a broad range of scientists in both academic and pharmaceutical settings. At the heart of this focus is the remarkable finding that this class of peptide structure delivers unprecedented and selective therapeutic benefit for a large range of disease areas that include oncology, algiatry, and neurology.[1] While many naturally occurring macrocycles have found medicinal applications over the last century, the use of non-natural cyclic peptides has become prominent due mainly to the advent of synthetic biology technologies that allow large numbers of these macrocyclic rings to be rapidly assembled and tested on micro scale.[2]

The success of cyclic peptides as a privileged pharmacophore can be attributed to i) conformational ring constraints and ii) enhanced pharmacokinetic (PK) properties in comparison to their acyclic counterparts.[3] With respect to the former, conformational rigidity can lead to increased biological activity and target selectivity by diminishing the entropic barrier in reaching the requisite binding conformation. In terms of PK considerations, reduced flexibility along with the absence of terminal amine and carboxylate functionalities lead to greater metabolic stability.[4] As a consequence, large cyclic peptides are often better suited than small molecules to selectively disrupt important biological binding events such as protein-protein interactions.[5]

Molecules belonging to the cyclic peptide structural class can be challenging to prepare by traditional synthetic methods.[6] In

graphic file with name nihms833804f3.jpg (Eq. 1)

contrast to all-carbon-backbone macrocycles, the ground state (E)-geometry of multiple acyclic amide bonds results in a relatively high entropic barrier for head-to-tail engagement, while for small peptide sequences, ring strain often prevents efficient cyclization. Chief among the difficulties inherent to the synthesis of peptidic macrocycles is bimolecular couplings in lieu of the desired intramolecular pathway, leading to linear oligomeric products. Selectivity for unimolecular head-to-tail cyclization can be achieved by performing reactions at low concentrations of substrate, the use of turn-inducing elements, or pseudo-dilution phenomena.[7] While traditional syntheses of macrocyclic peptides rely almost exclusively on coupling reagent mediated lactamization as the critical ring-forming step, in recent years a number of reports[8] have demonstrated the use of ring-closing metathesis, alkyne-azide cycloaddition, photochemical thiol-ene, and other elegant approaches to achieve macrocyclization.[9]

Our laboratory has recently introduced a number of photoredox mediated protocols in which α-sp3 carboxylic acids are used as activating groups to generate open-shell radical species (after decarboxylation) that can, thereafter, be employed in a number of C–C bond forming processes.[10] In one such example, a decarboxylative conjugate addition reaction was developed that is successful with a substantial range of carboxylic acid nucleophiles (Eq 1).[11] Given the aptitude with which α-amino carboxylates undergo single-electron transfer (SET)–decarboxylation to generate nucleophilic Csp3 radicals, we questioned whether the C-termini of linear peptide chains might be selectively functionalized via photoredox-mediated CO2-extrusion. As a key design element, we hypothesized that the resulting α-amino radicals might readily participate in intramolecular conjugate addition with pendant acrylamides, thereby enabling a rare example of C–C bond formation to close a cyclic peptide ring. Among a number of advantages, we recognized that this macrocyclization event i) would be triggered using innate functionality, namely the C-terminus carboxylate, without the need for acid prefunctionalization, ii) would be selective for oxidation of the C-terminus carboxylate group over other acid-containing residues (e.g., aspartate or glutamate side chains), iii) would require the replacement of only one amino acid unit with an unsaturated acid during synthesis, and iv) would introduce a non-peptidic section into the macrocycle, a feature that is known to generally improve the intrinsic pharmacokinetic profile while maintaining biological activity.[12] Herein, we report the successful execution of these ideals and present an intramolecular radical 1,4-addition platform applicable across a wide range of peptide ring sizes and amino acid residues. Importantly, by leveraging the C-terminal carboxylate group, peptide macrocyclization is photoredox-enabled using the inherent oxidation potentials of naturally occurring α-amino acids. As shown in Scheme 1, our proposed mechanism begins with visible light irradiation of photoredox catalyst Ir[dF(CF3)ppy]2(dtbbpy)+ (1) to access the excited state *Ir[dF(CF3)ppy]2(dtbbpy)+ (2), a strong oxidant (E1/2red[*IrIII/IrII] = +1.21 V vs SCE in MeCN).[13] Subsequent selective SET oxidation of the carboxylate salt of 3 (Ep/2red (Boc-Gly-CO2K) = +1.2 V vs SCE in MeCN)[14] would generate a carboxyl radical, which upon CO2-extrusion would produce α-amino radical 4 and the reduced photocatalyst (5). Intramolecular addition of nucleophilic α-amino radical 4 to the pendant Michael acceptor would then forge the desired macrocycle via a key C–C bond formation while furnishing electrophilic α-acyl radical 6. Closure of the photoredox catalytic cycle would then involve SET reduction of the electron-deficient radical 6 (E1/2red•CH(CH3)CO2CH3 = −0.66 V vs SCE; E1/2red[IrIII/IrII] = −1.37 V vs SCE)[15] by 5 to generate a macrocyclic enolate, which upon protonation would deliver desired cyclic peptide 7.[16]

Scheme 1.

Scheme 1

Proposed Decarboxylative Peptide Macrocyclization

We began our investigation into the proposed decarboxylative cyclization by exposing the N-acryloyl peptide Phe-Leu-Ala-Phe-Gly (3), photocatalyst 1, and K2HPO4 in DMF to a 34 W blue LED lamp at room temperature (Table 1). To our delight, intramolecular cyclic peptide formation was observed under these preliminary conditions, albeit with low yield (entry 1, 33% yield). As expected, lowering the concentration of the peptide substrate helped to circumvent oligomerization pathways while improving efficiency (entries 2 and 3). Similar increases in yield were observed with higher photocatalyst loadings, consistent with the necessary reduction of the α-acyl radical species in lieu of oligomerization (entry 4). It should be noted that the removal of base led to greatly diminished efficiency, and control experiments revealed that photocatalyst and light were critical for product formation (entries 5–7).

Table 1.

Initial Results and Optimization

graphic file with name nihms833804t1.jpg

entry conditions concentration 1 yielda
1 as shown 10 mM 8 mol% 33%
2 as shown 5 mM 8 mol% 63%
3 as shown 2.5 mM 8 mol% 72%
4 as shown 2.5 mM 12 mol% 86%
5 no base 2.5 mM 12 mol% 31%
6 no photocatalyst 2.5 mM 0 mol% 0%
7 no light 2.5 mM 12 mol% 0%
a

Yields determined by HPLC, see Supporting Information.

Having determined reaction conditions leading to efficient macrocyclization, we turned our attention to establishing the scope of competent peptide substrates. As shown in Table 2, pentamers that incorporate a structurally diverse set of amino acids are generally successful using this decarboxylative method. HMBC correlations and x-ray diffraction for examples 7 and 13 respectively unambiguously confirmed their cyclic nature.[17] Importantly, substrates containing many functional side chains can be cyclized readily under photoredox conditions (812, 34%–77% yield).[18] In the context of drug discovery, peptides containing N-methylated residues are particularly interesting due to increased membrane permeability and hydrophobicity.[19] Indeed, sequences containing the non-canonical amino acids N-methyl alanine and propargylglycine also undergo photoredox macrocyclization with excellent efficiency (12 and 13, 82% and 83% yield, respectively). As a critical design element for these studies, we hypothesized that high selectivity should be observed for decarboxylation of the α-amino acid C-terminal residue in preference to any side chain carboxylic acids, due to the lower pKa and oxidation potential. As such, we were delighted to observe that a substrate containing a Glu residue undergoes uniformly selective decarboxylation at the α-amino C-terminal residue in preference

graphic file with name nihms833804f4.jpg (Eq. 2)

to the γ-amino carboxylate side chain (15, 50% yield, 2:1 dr). This protocol is also amenable to terminal amino acid and Michael acceptor substitution, as shown in Table 3. Moreover, incorporating a radical-stabilizing phenyl group at the α-position of the α,β-unsaturated carbonyl results in excellent reaction efficiency and diastereocontrol (16, 85% yield, 10:1 dr). The use of N-methyl leucine at the precursor C-terminus also resulted in an efficient macrocyclization, albeit without control at the newly formed stereocenter (17, 51% yield, 1.6:1 dr). Notably, spirocenter-containing macrocycles can be readily generated (18 and 19, 51% and 56% yield, respectively).

Table 2.

Scope with Varied Amino Acid Residues

graphic file with name nihms833804t2.jpg
a

Yield determined by HPLC of crude reaction (2 trials), see Supporting Information. Isolated yield by preparative HPLC in parenthesis.

b

Added 10 mol% 2,4,6-triisopropylthiophenol.

Table 3.

Scope of C-Terminus and Acryloyl Functionality

graphic file with name nihms833804t3.jpg
a

Yields determined by HPLC of crude reaction (2 trials), see Supporting Information. Isolated yield in parenthesis.

b

DMSO as solvent.

Finally, we sought to assess the range of different ring sizes that could be generated (Table 4). Notably, peptide sequences containing 8, 10, and 15 amino acids (arbitrarily selected residue numbers) undergo efficient cyclization using this photoredox protocol (2123, 52–55% yield). It has long been established that medium peptidic ring synthesis is challenging due to the ground state (E)-conformation of the amide bond and detrimental transannular interactions. As such, we were delighted to find that a tripeptide substrate underwent intramolecular bond formation with useful levels of efficiency (20, 36% yield).

Table 4.

Scope of Peptide Macrocycle Ring Sizes

graphic file with name nihms833804t4.jpg
a

Yields determined by HPLC (2 trials), see Supporting Information. Isolated yield in parenthesis.

b

10 mol% of 2,4,6-triisopropylthiophenol.

Last, to highlight the utility of this technology for preparing cyclic structures of therapeutic value, we sought to construct COR-005, a somatostatin analog currently in Phase II clinical trials.[20] Somatostatin receptor agonists have shown high potential for the treatment of gastrointestinal indications, non-insulin dependent diabetes, and acromegaly.[21] The γ-amino acids serve to optimize the conformational rigidity and stability of the compound while not interfering with receptor-binding ability. Additionally, 25 is resistant to biodegradation in comparison to somatostatin. As shown in Eq 2, photoredox-mediated cyclization of linear peptide 24, followed by acid-mediated deprotection, leads to COR-005 (25) in 56% yield.

Supplementary Material

Supporting Information

Acknowledgments

The authors are grateful for financial support provided by the NIH General Medical Sciences (Grant NIHGMS (R01 GM078201-05) and gifts from Bristol-Myers Squibb, Merck and Abbvie. Purification of compounds was supported by Sergey Malnikov at BMS. X-ray diffraction was performed by Dr. Phil Jeffrey at Princeton University.

Contributor Information

Stefan J. McCarver, Merck Center for Catalysis at Princeton University, Washington Road, Princeton, NJ 08544, (USA)

Jennifer X. Qiao, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA)

Joseph Carpenter, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA).

Robert M. Borzilleri, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA)

Michael A. Poss, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA)

Martin D. Eastgate, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA)

Michael Miller, Bristol-Myers Squibb, Route 206 & Province Line Road, Princeton, NJ, 08543 (USA).

Prof. Dr. David W. C. MacMillan, Merck Center for Catalysis at Princeton University, Washington Road, Princeton, NJ 08544, (USA).

References

  • 1.a) Fairlie DP, Abbenante G, March DR. Curr. Med. Chem. 1995;2:654. [Google Scholar]; b) Wang S, Blois A, El Rayes T, Liu JF, Hirsch MS, Gravdal K, Palakurthi S, Bielenberg DR, Akslen LA, Drapkin R, Mittal V, Watnick RS. Sci. Transl. Med. 2016;8:329. doi: 10.1126/scitranslmed.aad5653. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Janecka A, Gentilucci L. Fut. Med. Chem. 2014;6:2093. doi: 10.4155/fmc.14.132. [DOI] [PubMed] [Google Scholar]; d) Thell K, Hellinger R, Sahin E, Michenthaler P, Gold-Binder M, Haider T, Kuttke M, Liutkevičiūtė Z, Göransson U, Gründemann C, Schabbauer G, Gruber CW. PNAS. 2016;113:3960. doi: 10.1073/pnas.1519960113. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.a) Driggers EM, Hale SP, Lee J, Terrett NK. Nat. Rev. Drug Discov. 2008;7:608. doi: 10.1038/nrd2590. [DOI] [PubMed] [Google Scholar]; b) Craik DJ, Fairlie DP, Liras S, Price D. Chem. Biol. Drug Des. 2013;81:136. doi: 10.1111/cbdd.12055. [DOI] [PubMed] [Google Scholar]; c) Yudin AK. Chem. Sci. 2015;6:30. doi: 10.1039/c4sc03089c. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Horton DA, Bourne GT, Smythe ML. J. Comput. Aided Mol. Des. 2002;16:415. doi: 10.1023/a:1020863921840. [DOI] [PubMed] [Google Scholar]
  • 3.a) Roxin A, Zheng G. Future Med. Chem. 2012;4:1601. doi: 10.4155/fmc.12.75. [DOI] [PubMed] [Google Scholar]; b) Adessi C, Soto C. Curr. Med. Chem. 2002;9:963. doi: 10.2174/0929867024606731. [DOI] [PubMed] [Google Scholar]
  • 4.a) Bogdanowich-Knipp SJ, Jois DSS, Siahaan TJ. J. Peptide Res. 1999;53:523. doi: 10.1034/j.1399-3011.1999.00055.x. [DOI] [PubMed] [Google Scholar]; b) Piserchio A, Salinas GD, Li T, Marshall J, Spaller MR, Mierke DF. Chemistry & Biology. 2004;11:469. doi: 10.1016/j.chembiol.2004.03.013. [DOI] [PubMed] [Google Scholar]
  • 5.a) Cardote TAF, Ciulli A. ChemMedChem. 2016;11:787. doi: 10.1002/cmdc.201500450. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Zhang Z, Lin Z, Zhou Z, Shen HC, Yan SF, Mayweg AV, Xu Z, Qin N, Wong JC, Zhang Z, Rong Y, Fry DC, Hu T. ACS Med. Chem. Lett. 2014;5:993. doi: 10.1021/ml500160m. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Davies JS. J. Peptide Sci. 2003;9:471. doi: 10.1002/psc.491. [DOI] [PubMed] [Google Scholar]
  • 7.Martí-Centelles V, Pandey MD, Burguete MI, Luis SV. Chem. Rev. 2015;115:8736. doi: 10.1021/acs.chemrev.5b00056. [DOI] [PubMed] [Google Scholar]
  • 8.a) White CJ, Yudin AK. Nat. Chem. 2011;3:509. doi: 10.1038/nchem.1062. [DOI] [PubMed] [Google Scholar]; b) Griesbeck AG, Heinrich T, Oelgemöller M, Molis A, Heidtmann A. Helv. Chim. Acta. 2002;85:4561. [Google Scholar]; c) Zhang L, Tam JP. J. Am. Chem. Soc. 1997;119:2363. [Google Scholar]; d) Yu L, Lai Y, Wade JV, Coutts SM. Tetrahedron Lett. 1998;39:6633. [Google Scholar]
  • 9.a) Miller SJ, Blackwell HE, Grubbs RH. J. Am. Chem. Soc. 1996;118:9606. [Google Scholar]; b) Punna S, Kuzelka J, Wang Q, Finn MG. Angew. Chem. Int. Ed. 2005;44:2215. doi: 10.1002/anie.200461656. [DOI] [PubMed] [Google Scholar]; c) Aimetti AA, Shoemaker RK, Lin C-C, Anseth KS. Chem. Commun. 2010;46:4061. doi: 10.1039/c001375g. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Wang Y, Chou DH-C. Angew. Chem. Int. Ed. 2015;54:10931. doi: 10.1002/anie.201503975. [DOI] [PubMed] [Google Scholar]
  • 10.a) Zuo Z, Ahneman DT, Chu L, Terrett JA, Doyle AG, MacMillan DWC. Science. 2014;345:437. doi: 10.1126/science.1255525. [DOI] [PMC free article] [PubMed] [Google Scholar]; b) Noble A, McCarver SJ, MacMillan DWC. J. Am. Chem. Soc. 2015;137:624. doi: 10.1021/ja511913h. [DOI] [PMC free article] [PubMed] [Google Scholar]; c) Zuo Z, Cong H, Li W, Choi J, Fu GC, MacMillan DWC. J. Am. Chem. Soc. 2016;138:1832. doi: 10.1021/jacs.5b13211. [DOI] [PMC free article] [PubMed] [Google Scholar]; d) Noble A, MacMillan DWC. J. Am. Chem. Soc. 2014;136:11602. doi: 10.1021/ja506094d. [DOI] [PMC free article] [PubMed] [Google Scholar]; e) Zuo Z, MacMillan DWC. J. Am. Chem. Soc. 2014;136:5257. doi: 10.1021/ja501621q. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Chu L, Ohta C, Zuo Z, MacMillan DWC. J. Am. Chem. Soc. 2014;136:10886. doi: 10.1021/ja505964r. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.a) Oddo A, Nyberg NT, Frimodt-Møller N, Thulstrup PW, Hansen PR. Eur. J. Med. Chem. 2015;102:574. doi: 10.1016/j.ejmech.2015.08.028. [DOI] [PubMed] [Google Scholar]; b) Chen Y-C, Muhlrad A, Shteyer A, Vidson M, Bab I, Chorev M. J. Med. Chem. 2002;45:1624. doi: 10.1021/jm010479l. [DOI] [PubMed] [Google Scholar]; c) Ohshiro Y, Nakajima E, Goto Y, Fuse S, Takahashi T, Doi T, Suga H. ChemBioChem. 2011;12:1183. doi: 10.1002/cbic.201100104. [DOI] [PubMed] [Google Scholar]
  • 13.Lowry MS, Goldsmith JI, Slinker JD, Rohl R, Pascal RA, Jr, Malliara GG, Bernhard S. Chem. Mater. 2005;17:5712. [Google Scholar]
  • 14.Reported as half peak potential. See Supporting Information.
  • 15.Bortolamei N, Isse AA, Gennaro A. Electrochim. Acta. 2010;55:8312. [Google Scholar]
  • 16.Detailed mechanistic investigations are ongoing.
  • 17.See Supporting Information. CCDC 1507663 contains the supplementary crystallographic data for this paper. These data can be obtained free of charge from The Cambridge Crystallographic Data Centre via www.ccdc.cam.ac.uk/data_request/cif.
  • 18.For several substrates, addition of a thiol co-catalyst led to increased efficiency. See Supporting Information for details.
  • 19.a) Chatterjee J, Rechenmacher F, Kessler H. Angew. Chem. Int. Ed. 2013;52:254. doi: 10.1002/anie.201205674. [DOI] [PubMed] [Google Scholar]; b) White TR, Renzelman CM, Rand AC, Rezai T, McEwen CM, Gelev VM, Turner RA, Linington RG, Leung SSF, Kalgutkar AS, Bauman JN, Zhang Y, Liras S, Price DA, Mathiowetz AM, Jacobson MP, Lokey RS. Nat. Chem. Biol. 2011;7:810. doi: 10.1038/nchembio.664. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hornik V, Afargan M, Gellerman G. WO 99/65508. 1999 Dec 23;
  • 21.Plöckinger U, Hoffmann U, Geese M, Lupp A, Buchfelder M, Flitsch J, Vajoczy W, Saeger W, Schulz S, Dohrmann C. Eur. J. Endocrinol. 2012;166:223. doi: 10.1530/EJE-11-0737. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supporting Information

RESOURCES